Onivyde (Irinotecan Liposomal) Patent Expiration, LOE Window & CMS Spending

Onivyde (Irinotecan Liposomal) by Ipsen Biopharmaceuticals: FDA Orange Book core substance LOE 2028-08-29 (last listed 2036-10-15), 0 AB generics, $10.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIpsen Biopharmaceuticals
FDA Application & PathwayN207793 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2028-08-29
Last Listed Patent or Exclusivity Date2036-10-15
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.1M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$7.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel